PFS by blinded independent central review (BICR) in the VELIA trial of veliparib (V) plus carboplatin/paclitaxel (CP) and as monotherapy in newly diagnosed patients (pts) with high-grade serous ovarian cancer (HGSC) Meeting Abstract
| Authors: | Aghajanian, C.; Bookman, M. A.; Fleming, G. F.; Brady, M. F.; Swisher, E. M.; Steffensen, K. D.; Friedlander, M.; Okamoto, A.; Moore, K. N.; Sullivan, D. M.; Fallstrom, M.; Dinh, M.; Ratajczak, C.; Coleman, R. L. |
| Abstract Title: | PFS by blinded independent central review (BICR) in the VELIA trial of veliparib (V) plus carboplatin/paclitaxel (CP) and as monotherapy in newly diagnosed patients (pts) with high-grade serous ovarian cancer (HGSC) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Start Page: | 347s |
| Language: | English |
| ACCESSION: | WOS:000560368302501 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.6077 |
| Notes: | Meeting Abstract: 6077 -- Source: Wos |
